
Genpact fell 6.4% from $44.36 to $41.50, behind the S&P 500's +4.7%. Its worst day was Feb 3 (−11.7%), and its low came Jun 30 at $27.50.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Genpact closed at its highest level of the year, 9.3% above where the year started.
+1.2% · S&P 500 +0.6%
EPS of $0.97 beat the $0.89 estimate on $1.1B revenue (est. $1.3B); FY revenue guidance of $5.4B against the $5.4B consensus.
Story events cover the past 12 months · Times ET
+7.1%, on 6M shares, the year's heaviest volume · S&P 500 +1.9%
EPS of $0.98 beat the $0.90 estimate on $1.3B revenue (est. $1.3B); Q2 revenue guidance of $1.3B–$1.3B against the $1.3B consensus.
−5.6% · S&P 500 +0.8%
Genpact shares rose 7.9%, while the S&P 500 fell 0.1%.
+7.9%, the year's best day · S&P 500 −0.1%
Genpact shares fell 6.8%, while the S&P 500 rose 1.0%.
−6.8% · S&P 500 +1.0%
Genpact closed at its lowest level of the year, 38.0% below where the year started.
−1.3% · S&P 500 +0.8%
Genpact shares rose 7.6%, while the S&P 500 rose 0.2%.
+7.6% · S&P 500 +0.2%
EPS of $1.00 beat the $0.94 estimate on $1.3B revenue (est. $1.3B); FY revenue guidance of $5.4B against the $5.4B consensus.
−5.2% · S&P 500 +0.6%
Genpact shares rose 6.7%, while the S&P 500 rose 0.2%.
+6.7% · S&P 500 +0.2%
EPS of $1.07 beat the $1.02 estimate on $1.4B revenue (est. $1.4B); Q4 revenue guidance of $1.2B against the $1.4B consensus.
+2.8% · S&P 500 +0.3%
Where it ended: a close of $41.50 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 4, 2027 (EPS est. $1.07, revenue est. $1.4B).
As of the Nov 20, 2026 close
Replay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for G and SPY from Benzinga historical bars. Not investment advice.